Head of Clinical Curation and Genomic Reporting Lead Vidium Animal Health Phoenix, Arizona, United States
Abstract: Genomics-guided precision medicine has revolutionized human oncology. Genomic knowledge, diagnostics, and novel therapeutics are now also increasingly available for canine cancers. A need still exists for the continued expansion of this genomic understanding. To define the clinical utility of genomic diagnostics for guiding cancer management in canine patients, we report on mutations and biomarkers identified by SearchLight DNA®, a canine cancer gene sequencing panel, in 693 canine cancer cases. Cancer tissue from 693 dogs was collected via retrospective study of biobanked material as well as through clinical cases submitted for SearchLight DNA analysis. For genomic analysis, SearchLight DNA is an analytically validated next-generation sequencing-based, 120-gene panel, designed to detect most cancer-driving mutation types. For biomarker annotation, Vidium InsightTM is a canine precision oncology biomarker knowledgebase containing over 4000 mutational biomarkers with diagnostic, prognostic and therapeutic associations, used to annotate candidate pathogenic and clinically relevant mutations from sequenced cases. We identified 6582 (927 unique) mutations in 103 genes for 693 cases, of which, 644 harbored mutations previously detected in canine or human cancer, and associated with diagnostic, prognostic, and/or therapeutic indications (actionable yield: 92.9%). Over 50 well-defined cancer histologies were analyzed, 19 with at least 5 cases (actionable yield: 72.2% - 100%; Median: 95.8%). Notably, this study comprises the first in-depth genomic analysis of 11 of these 19 types. We present mutation data with structured biomarker annotation across 693 samples and 50 cancer types, providing unprecedented insight into the genomic underpinnings and clinical actionability of canine cancers.
